Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative Pharmaceuticals and Long-term Care Insurance (LTCI) - **Key Companies Mentioned**: - Innovative Pharmaceuticals: 石药集团 (Shiyao Group), 信达生物 (Innovent Biologics), 恒瑞医药 (Hengrui Medicine), 百济神州 (BeiGene), 康方生物 (CanSino Biologics), 英矽智能 (Insilico Medicine), and others - Long-term Care Insurance: 鱼跃医疗 (Yuyue Medical), 可孚医疗 (Cofe Medical) Core Insights and Arguments 1. **Innovative Pharmaceuticals Recovery**: The recovery in the innovative pharmaceuticals sector since early 2026 is attributed to better-than-expected industry progress, significant business development (BD) projects, and supportive government policies. Notable projects include large BD initiatives from 石药集团 and 信达生物, which have catalyzed market optimism [2][3] 2. **AI Drug Development**: AI in drug development is entering a validation phase, with 英矽智能's 05 pipeline showing potential to reverse lung function decline in idiopathic pulmonary fibrosis (IPF). Successful phase III trials could reshape global valuations in AI pharmaceuticals [1][10] 3. **Pancreatic Cancer Treatment**: The RAS inhibitors combined with PMT5 small molecules are expected to break through treatment barriers for pancreatic cancer, marking a significant year for targeted therapies in this area [1][10] 4. **Long-term Care Insurance Policy**: The government aims to establish a long-term care insurance system within three years, with a premium rate capped at 0.3%. This is expected to benefit home/community care services and related medical device companies [1][5] 5. **Shift in Small Nucleic Acid Drugs**: The focus of small nucleic acid drugs is shifting from rare diseases to chronic diseases, with domestic companies developing long-acting injection solutions to replace oral medications [1][15] Investment Opportunities 1. **Investment Lines**: - **Overseas Big Pharma BD 2.0**: Focus on companies that have successfully achieved overseas product authorization, such as 科伦博泰, 信立泰, and others [4] - **Tech Revolution in Small/Mid-Cap Firms**: Emphasis on unique technology platforms in fields like small nucleic acids and CAR-T therapies, with recommended stocks including 英诺维, 乐普生物, and others [4] - **Valuation Reassessment of Traditional Pharma**: Companies like 恒瑞医药 and 信立泰 are highlighted for potential value reassessment [4] 2. **CRO/CDMO Opportunities**: The supply chain upstream, including CRO/CDMO sectors, is also seen as a promising area for investment, with companies like 泰格医药 and 药明康德 being noteworthy [4] Additional Important Insights - **Market Dynamics**: The innovative pharmaceuticals sector is experiencing a rebound due to a significant underweight position in public funds as of Q4 2025, providing a foundation for recovery [2] - **Clinical Data Releases**: Upcoming critical clinical data releases from companies like 信立泰 and 科伦博泰 are expected to sustain market momentum [2] - **Healthcare Equipment Performance**: Recent performance in the medical device sector has been mixed, with notable gains in companies like 九安医疗 and 康拓医疗, driven by AI asset revaluation and new product launches [16][17] - **Long-term Care Insurance Framework**: The LTCI policy aims to cover a broad demographic, starting with employed and retired individuals, and gradually including unemployed residents, with a focus on community-based care [5] This summary encapsulates the key points from the conference call records, highlighting the innovative pharmaceuticals sector's recovery, the impact of AI in drug development, and the establishment of long-term care insurance in China.

Core Insights - The Chinese innovative drug industry experienced a strong start in Q1 2026, with total licensing-out transactions exceeding $60 billion (approximately 414.6 billion RMB), nearing half of the total for 2025 [1] - The National Medical Products Administration approved 10 innovative drugs by March 27, 2026, with 8 being domestically developed, marking a historical high for the same period [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index surged by 6.1% on March 27, reflecting strong investor confidence in the sector [1] Industry Structure - The Chinese innovative drug industry has established a complete closed-loop structure comprising upstream support, midstream R&D and production, and downstream commercialization, with each segment closely linked and clearly defined [2] - Upstream, the production of active pharmaceutical ingredients (APIs) reached 3.504 million tons in 2024, with the intermediate market exceeding 255.2 billion RMB, achieving self-sufficiency in most basic raw materials [2] - The midstream segment is characterized by high technical barriers and significant capital investment, with projections indicating that the market size could exceed $300 billion by 2030, increasing China's global market share [2] - Downstream commercialization involves reaching patients through medical institutions and retail pharmacies, with medical insurance and commercial insurance as key payers [2] Global Positioning - China has transitioned from being a "global follower" to a leading player in innovative drug R&D, with 7 out of the top 10 global pharmaceutical licensing transactions in 2025 originating from Chinese companies [3] - The focus of R&D is on oncology (519 clinical trials), hematological diseases (182), and immune diseases (146), with ADCs and bispecific antibodies showing the fastest growth [3] Financial Support - The availability of funds is crucial for the long-term development of the innovative drug industry, with BD (business development) income becoming a significant funding source for Chinese pharmaceutical companies [3] - Most domestic pharmaceutical firms maintain over a year of R&D funding coverage, supporting clinical trial progress and pipeline expansion [3] Challenges and Competition - Despite rapid growth, the industry faces challenges such as homogenization of hot targets, exemplified by the PD-1/PD-L1 inhibitors, where over ten products have been approved, leading to intense market competition and price wars [4] - The ADC sector is also crowded, with numerous projects in development, increasing commercialization pressure [4] Future Outlook - Since 2015, supportive policies for domestic innovative drugs have accumulated, driving rapid development, with expectations for significant advancements during the 14th Five-Year Plan period [4] - New drug forms such as small nucleic acid drugs and precision therapy CGT products are anticipated to reach a harvest period, facilitating a shift from "generic innovation" to "original innovation" in the Chinese innovative drug industry [4] Industry Players - Key upstream companies include Tianyu Co., Shandong Pharmaceutical Glass, and Senxuan Pharmaceutical, focusing on raw materials and production [5][6] - Midstream leaders include WuXi AppTec and Hengrui Medicine, known for their integrated platforms and significant partnerships [6] - Downstream players like Kefu Medical and Laobaixing Pharmacy are pivotal in retail and distribution, with extensive networks [6]

Group 1: Industry Insights - The article discusses various upcoming webinars focusing on different industries, including transportation, machinery, AI, finance, automotive, and pharmaceuticals [1][32]. - Each session is led by a specialized analyst, indicating a structured approach to industry analysis and insights [1][32]. Group 2: Webinar Schedule - The first session on March 29 focuses on the analysis of Zhongyuan Expressway, led by Cheng Zhifeng, a transportation analyst [1][32]. - The second session on March 30 will update on the machinery industry, presented by Cui Wenjuan, the chief machinery analyst [1][32]. - Another session on March 30 will delve into AI video developments, highlighting model acceleration and the value of tools and IP, led by Zheng Lei and Li Linhui [1][32]. - On April 1, there will be a review and update of the industry allocation model, presented by Liu Xiaofeng, the chief quantitative analyst [1][32]. - The April 2 session will revisit Elon Musk's V3 moment, focusing on Optimus V3 and Starship V3, led by Liu Hongchen, the chief automotive analyst [1][32]. - The final session on April 3 will cover the small nucleic acid industry, specifically the path to drug development, presented by Zhou Yu and Rong Xiaojie, both pharmaceutical analysts [1][32].

Group 1: Key Insights on Small Nucleic Acid Drugs - Small nucleic acids are chemically synthesized short nucleic acid sequences used to regulate gene expression levels, providing a direct method for disease treatment through mRNA transcription regulation [3] - Small nucleic acid drugs include small interfering RNA (siRNA), antisense oligonucleotides (ASO), and aptamers, which operate through different mechanisms to modulate gene expression and protein levels [3] - Compared to small molecules and antibody drugs, small nucleic acid drugs have advantages such as longer dosing cycles and improved safety profiles [3] Group 2: Investment Strategy in New Quality Production Forces - The current market is experiencing a structural divergence between short-term macro disturbances and long-term industrial trends, with geopolitical conflicts and delayed interest rate cuts suppressing market risk appetite [4] - The "new quality productivity" industrial trend, driven by aerospace, artificial intelligence, and high-end equipment, is accelerating under strong policy support and technological breakthroughs, indicating solid long-term growth logic for related hard technology assets [4] - Investment recommendations focus on three main lines: the entire commercial aerospace industry chain, artificial intelligence and robotics, and high-end equipment and material localization [5] Group 3: Anta Sports Performance - Anta Sports is projected to achieve a revenue growth of 13.3% to 80.219 billion yuan in 2025, with a net profit growth of 13.9% after excluding one-time gains [6] - The company reported a gross margin of 62.0%, a slight decrease of 0.2 percentage points year-on-year, and an operating profit increase of 15.0% to 19.091 billion yuan [6] - The expected net profit for 2026 is 14.053 billion yuan, corresponding to a PE ratio of 13 times, with further growth anticipated in 2027 and 2028 [6] Group 4: Coal Industry Insights from Power Development - Power Development reported a revenue of 5.293 billion yuan in 2025, a decrease of 6.4% year-on-year, with a net profit of 896 million yuan, down 57.5% [7] - The company is expanding its overseas business, particularly in South Africa, with significant coal resources and projects expected to contribute to future profitability [8] - The projected annual profit from the Ningxia coal mine is estimated at 7 to 8 billion yuan, while the Makhado project in South Africa is expected to generate at least 100 million USD annually [9] Group 5: China National Materials' Business Optimization - China National Materials achieved a revenue of 49.6 billion yuan in 2025, a year-on-year increase of 7.5%, with a significant growth in overseas business [14] - The company’s net profit was 2.86 billion yuan, a decrease of 4% primarily due to increased impairment provisions [14] - Future net profit projections for 2026-2028 are 3.2 billion, 3.5 billion, and 3.7 billion yuan, respectively, indicating a stable growth trajectory [14]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid drug industry Core Insights - The small nucleic acid drug market is experiencing strong and sustained growth, projected to increase from $2.7 billion in 2019 to $5.7 billion by 2024, with a compound annual growth rate (CAGR) of 16.2% [4] - By 2029 and 2034, the market is expected to reach $20.6 billion and $54.9 billion, respectively, with a CAGR of 29.4% from 2024 to 2029 and 21.6% from 2029 to 2034 [4] - The report highlights the expansion of small nucleic acid drugs from liver-targeting to brain and fat-targeting applications, with ongoing clinical progress in areas such as lipid reduction, weight loss, and hypertension [5] Summary by Sections Section 1: Restructuring the Modern Pharmaceutical Landscape - Small nucleic acids are chemically synthesized short nucleic acid sequences that regulate gene expression levels, providing a direct method for disease treatment [3][14] - The main types of small nucleic acid drugs include small interfering RNA (siRNA), antisense oligonucleotides (ASO), and aptamers, each functioning through different mechanisms to modulate gene expression and protein levels [3][14] Section 2: Commercialization and Business Development - The global small nucleic acid drug market is projected to grow significantly, with 23 approved small nucleic acid drugs as of March 2026, including 12 ASO drugs and 8 siRNA drugs [41] - The number of transactions and total transaction value in the small nucleic acid field is on the rise, with a transaction value of $32.21 billion and 46 transactions in 2025 [47][50] Section 3: New Indications and Extensions - Small nucleic acid drugs are expanding their therapeutic applications beyond liver targets to include brain and fat targeting, with ongoing clinical trials in various conditions [5][57] - The report lists several companies involved in the development of small nucleic acid drugs, including domestic firms like Frontline Bio and Reborn Bio, as well as international companies like Alnylam and Arrowhead [7][41]

Core Viewpoint - The article discusses the upcoming 2026 Spring Conference organized by Guotai Junan Securities, focusing on macroeconomic policies, asset allocation strategies, and industry-specific insights, particularly in technology and finance sectors [1][2]. Group 1: Macroeconomic Insights - The conference will feature discussions on global monetary policy changes and asset outlooks, highlighting the evolving international order and its impact on investment strategies [3][5]. - Key sessions will include a roundtable on ETF allocation strategies and macroeconomic forecasts for 2026, emphasizing the importance of adapting to new economic realities [3][4]. Group 2: Industry-Specific Strategies - The telecommunications sector will be a focal point, with sessions dedicated to fiber optic demand analysis and the future of satellite communication technologies [6][7]. - The conference will also explore advancements in AI and its implications for wealth management, showcasing new trends in resident wealth management and non-bank strategies [10][11]. Group 3: Investment Opportunities - The event will address investment opportunities in the beauty industry, using Proya as a case study to illustrate successful strategies in a competitive market [14]. - Discussions will include the exploration of new technologies in the medical field, such as RNAi platforms and brain-machine interfaces, indicating a growing interest in biotech investments [20][21]. Group 4: Global Geopolitical Context - The conference will analyze the current geopolitical landscape, including U.S.-China relations and their implications for global asset allocation [7][8]. - A roundtable will focus on the strategic reassessment of Chinese hard assets in light of international order reconstruction, emphasizing the need for adaptive investment strategies [7][8].

Group 1 - The article discusses the upcoming Guotai Haitong Spring Strategy Conference scheduled for March 25, 2026, in Shenzhen, focusing on innovative breakthroughs and global value opportunities [1] - Key topics include the exploration of long-term precise weight loss and metabolic benefits through a new generation RNAi technology platform, presented by Meng Na, Vice President of Capital Markets at Saint Gene Biotech [1] - Other presentations will cover applications and prospects of brain-machine interfaces and neuro-regulation medical technologies, as well as advancements in lipid management through small nucleic acid drugs, presented by industry experts [1]

Group 1 - The report highlights a shift in China's innovative drug development from "fast-following" to "innovation-leading," potentially reshaping the global new drug development landscape. Key emerging technology platforms include molecular glue, small nucleic acids, and in vivo CAR-T, with Chinese companies making significant investments in these areas [3][4]. - Molecular glue offers a new paradigm for targeting "undruggable" targets, with significant potential in the PAN-RAS space. Companies to watch include Heng Rui Medicine, Jinfang Medicine, Yuandong Biology, and Betta Pharmaceuticals [3]. - Small nucleic acids are expanding from rare diseases to chronic conditions, with numerous companies involved in hypertension, dyslipidemia, weight loss, MASH, and CNS diseases. Notable companies include Heng Rui Medicine, Shiyao Group, and Innovent Biologics [3]. - In vivo CAR-T technology is cost-effective and enhances accessibility, showing promise in oncology and autoimmune diseases. Key players include Yunding Xinyao and Kexi Pharmaceuticals [3]. - The integration of AI in healthcare and drug development is accelerating, with companies like Runda Medical and Kangzhong Medical leading the way [3]. Group 2 - The report reviews the performance of the pharmaceutical sector in 2025, noting a cumulative increase of 11.9% in the pharmaceutical index, while the broader market rose by 30.2%, indicating a relative underperformance of 18.3% [8][14]. - The valuation of the pharmaceutical sector has slightly improved, with the PE (TTM) ratio rising from 29.8x at the beginning of 2025 to 36.2x by year-end, while the broader market's PE increased from 28.6x to 39.5x [14]. - The pharmaceutical sector's revenue for the first three quarters of 2025 reached CNY 18,544 billion, with a year-on-year decline of 0.4%, and net profit attributable to shareholders was CNY 1,407 billion, down 0.8% year-on-year [17][22]. Group 3 - The report indicates that the number of IND (Investigational New Drug) applications for innovative drugs in 2025 reached 3,626, marking a year-on-year growth of 10.4%. The number of NDA (New Drug Application) submissions also increased, with 83 for chemical drugs and 271 for therapeutic biological products [31][29]. - The report emphasizes the growing trend of molecular glue technology, particularly in targeting RAS mutations, which are prevalent in approximately 30% of malignancies. The representative drug Daraxonrasib has shown significant clinical efficacy [53][50]. - The report notes an increase in collaboration and licensing activities in the molecular glue sector, with major pharmaceutical companies engaging in high-value transactions, indicating a robust interest in this innovative technology [54][56].

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their applications from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways of Small Nucleic Acid Drug Development - ASO and siRNA represent two distinct technological pathways, with ASO focusing on RNA degradation and splicing regulation, while siRNA employs the RISC mechanism for mRNA degradation [12][26] Chemical Modifications and Stability - The report outlines four generations of chemical modifications that enhance the stability and specificity of ASO, which are crucial for their therapeutic efficacy [32][36] Delivery Breakthroughs - The report identifies the challenges of delivering small nucleic acids across cellular barriers, emphasizing the need for effective delivery systems to overcome these obstacles [40][43] Safety Optimization - Innovations in safety management, such as the development of antidotes for siRNA and toxicity control for ASO, are essential for supporting long-term use and chronic disease management [3][62] Commercialization and Boundary Expansion - The industry is moving from liver-targeted therapies to exploring delivery strategies for other tissues, with companies like Alnylam aiming for multi-organ delivery by 2030 [60][61]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]